GlassScriptPhysician profile
Keith M Simnicht
NPI 1851400410
$5,308.81
in general payments reported to CMS, 2019-2025
32 companies · $973 in 2025
The $973 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $374 · 2021: $529 · 2022: $784 · 2023: $682 · 2024: $1,607 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,262.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $1,088.41 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $909.36 | 2022-2025 | Qelbree |
| Corium, LLC | $665.44 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $416.43 | 2019-2024 | Jornay Pm |
| Novo Nordisk INC | $346.66 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $285.18 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $233.96 | 2019-2022 | |
| Noven Therapeutics, LLC | $159.65 | 2024-2025 | Xelstrym |
| Pfizer INC. | $110.14 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $105.95 | 2019-2022 | |
| Abbvie INC. | $92.36 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $87.87 | 2019-2022 | |
| Amarin Pharma, INC. | $83.50 | 2019-2021 | |
| Astellas Pharma US INC | $79.78 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.98 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $64.70 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.06 | 2022 | |
| Shire North American Group INC | $53.44 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $46.23 | 2021 | |
| Nestle Healthcare Nutrition INC. | $45.64 | 2021-2022 | |
| Amgen INC. | $42.76 | 2020-2022 | |
| Glaxosmithkline, LLC. | $39.16 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.31 | 2022 | |
| Daiichi Sankyo INC. | $31.04 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $28.08 | 2019 | |
| Genentech USA, INC. | $25.59 | 2019 | |
| Allergan, INC. | $23.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $19.60 | 2022 | |
| Lilly USA, LLC | $17.27 | 2022 | |
| Medtronic, INC. | $14.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.97 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Simnicht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.